BioSpace News Archive

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced receipt of U.S. Food and Drug Administration (“FDA”) approval for an improved surgical implant procedure that eliminates one incision with a revised placement of the pressure sensing lead.

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended December 31, 2020.

The International Society on Thrombosis and Haemostasis (ISTH) recommends that all eligible adults continue to receive their COVID-19 vaccinations, despite the recent decisions by Denmark, Norway and Iceland to at least temporarily suspend the use of the AstraZeneca vaccine due to reports of thrombosis.

Predictive Oncology (NASDAQ: POAI) – Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended December 31, 2020 and provided an update on business activities.

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Health Care Service Corporation (HCSC) has released a coverage policy for The Sonata® Procedure.

In light of the ongoing COVID-19 situation, the Company strongly encourages registered shareholders and proxyholders not to attend the AGM in person, and Shareholders are encouraged to vote using one of the methods described in the Management Information Circular (“MIC”) which can be viewed on SEDAR.

Mr. Bahl brings over 20 years of experience in pharmaceutical marketing and clinical development. He is the CEO and founder of RAS LSS, a boutique healthcare consulting group based in Germany.

Relay is a founding shareholder of Glow and recently added to its position by participating in Glow’s RTO financing on February 9, 2021, which was oversubscribed at over $5.1 million raised.

Post-COVID-19, what could be more valuable than an ‘all in one’, interactive infectious disease platform that can be used on any electronic device, provides the latest data and is used worldwide by medical scientists, physicians, microbiologists and students?

Demand for all types of genetic tests is exploding. This sector of clinical laboratory testing is robust and ever-more physicians are ordering genetic tests for a wide range of health conditions, causing a rapid increase in the number of genetic test orders flowing into the nation’s labs.